Alzheimer's disease metabolic and glucosamine research

Research published in Nature Metabolism and studies from the University of Florida have identified potential metabolic links to Alzheimer’s disease progression. Animal models suggest that hyperglycosylation—an increase in carbohydrate structures attached to proteins—may drive disease progression, and that reducing N-glycosylation activity could improve memory performance.

In human observational data, University of Florida researchers used artificial intelligence to analyze patient records from 2012 to 2024. Their findings suggest that glucosamine, a common over-the-counter joint supplement, is associated with a 25% higher likelihood of progressing from mild cognitive impairment to dementia. Additionally, among patients already diagnosed with Alzheimer’s disease and related dementias, glucosamine use was linked to a 25% higher mortality risk.

Lead researcher Ramon Sun and his team emphasized that these findings are based on a retrospective analysis of health records and show an association rather than direct causation. The research combined medical record analysis with animal models and human brain tissue examinations to explore biological mechanisms involving glucosamine metabolism. Researchers noted that while these findings do not prove causation, the strength of the signal warrants controlled human clinical trials to investigate the relationship between glucosamine metabolism and Alzheimer’s-related biological processes.